The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

According to The Business Research Company’s “Thyroid Cancer Drugs Global Market Report 2023,” the global thyroid cancer drugs market will increase from $0.71 billion in 2022 to $0.81 billion in 2023, with a 14.0% CAGR. By 2027, it’s projected to reach $1.29 billion, growing at a 12.5% CAGR.

What was the major driver in the thyroid cancer drugs market?
Rising thyroid cancer cases, primarily in women, propel the thyroid cancer drugs market. In 2022, The American Cancer Society estimated around 43,800 new thyroid cancer cases in the United States, with 31,940 in women and 11,860 in men, resulting in 2,230 deaths (1,070 in men and 1,160 in women). This surge in thyroid cancer, especially among women, fuels industry growth.

View More On The Thyroid Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

What was the key trend in the thyroid cancer drugs market?
Combination drugs gain traction in thyroid cancer treatment, enhancing effectiveness and halting cancer progression. These drugs contain multiple active pharmaceutical ingredients (APIs) in a single dosage form, curbing drug resistance and cancer cell growth. For example, the FDA approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) to treat anaplastic thyroid cancer.

Which was the largest region in the thyroid cancer drugs market?
North America was the largest region in the thyroid cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global thyroid cancer drugs market during the forecast period. The regions covered in the global thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Who are the thyroid cancer drugs market prominent players?
Major players in the thyroid cancer drugs market are Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc., Baxter International Inc., Abbott laboratories, App pharmaceuticals llc., AstraZeneca PLC and GlaxoSmithKline PLC.

Key thyroid cancer drugs market segments
The global thyroid cancer drugs market is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users
3) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

Request A Sample Of The Global Thyroid Cancer Drugs Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=2601&type=smp

The Thyroid Cancer Drugs Global Market Report 2023  provides a comprehensive overview on the thyroid cancer drugs market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Drugs For Immunotherapy Global Market Report 2023
Drugs For Erectile Dysfunction Global Market Report 2023
Pancreatic Cancer Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model